OZURDEX
® (dexamethasone intravitreal implant) 0.7 mg is a biodegradable
implant injected into the eye (vitreous) to treat adults with macular edema following
branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) and
to treat adults with noninfectious uveitis affecting the posterior segment of the
eye.
Why did my doctor choose OZURDEX®?
OZURDEX
® has been approved by the US Food and Drug Administration
(FDA) to treat adults with macular edema following BRVO or CRVO and to treat adults with noninfectious uveitis affecting the posterior segment of the eye. Your doctor will discuss with you the reasons why OZURDEX
® was selected
as well as the benefits and risks of treatment.
The OZURDEX® implant is so tiny that it can be injected into the
eye (vitreous) with a procedure in your doctor’s office. Each implant is already
inside a special applicator device that is needed to perform the insertion. The
implant will be injected into the vitreous humor inside your eye. This is known as an intravitreal injection.
Inside the eye, the implant is slowly dissolved by the vitreous gel that fills the
eye, releasing medicine to decrease the swelling or inflammation.
Who should not receive OZURDEX®?
You should not receive OZURDEX® if you have an eye infection in or
near your eye (including herpes viral infection of the eye; vaccinia; varicella;
mycobacterial infections; and fungal diseases); if you have advanced glaucoma; or
if you are allergic to corticosteroids or to any other ingredient of OZURDEX®
intravitreal implants.
Please scroll down to see additional Important Safety Information.
Click one of the buttons below to learn more about OZURDEX® and your
condition:
Or go to one of these pages: